SCHEMBL397179

SCHEMBL397179

Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1NC(=O)Nc1ccc2c(c1)NC(=O)C2=Cc1c(C)c(C(=O)O)c(C)n1C(C(N)=O)N1CCCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NTRK1 P04629 8/20 0.48
▸ NTRK3 Q16288 3/20 0.46
▸ NTRK2 Q16620 5/20 0.45
▸ KIT P10721 4/20 0.45
▸ CSF1R P07333 4/20 0.45
▸ FLT3 P36888 3/20 0.45
▸ SRC P12931 2/20 0.45
▸ JAK2 O60674 1/20 0.45
▸ ABL1 P00519 1/20 0.45
▸ INSR P06213 1/20 0.45
▸ LYN P07948 1/20 0.45
▸ RET P07949 1/20 0.45
▸ IGF1R P08069 1/20 0.45
▸ MET P08581 1/20 0.45
▸ ROS1 P08922 1/20 0.45
▸ PDGFRB P09619 1/20 0.45
▸ FGR P09769 1/20 0.45
▸ FLT1 P17948 1/20 0.45
▸ FGFR4 P22455 1/20 0.45
▸ FGFR3 P22607 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL399113 0.94 NTRK1 (0.51) NTRK1NTRK3NTRK2KITFLT3
SCHEMBL396344 0.92 FLT3 (0.47) NTRK1NTRK3NTRK2KITCSF1R
SCHEMBL394096 0.92 NTRK1 (0.56) NTRK1NTRK3NTRK2KITFLT3
SCHEMBL394130 0.91 NTRK1 (0.56) NTRK1NTRK3NTRK2KITFLT3
SCHEMBL396420 0.87 MAPK14 (0.45) NTRK1NTRK3NTRK2KITCSF1R
SCHEMBL396423 0.87 FLT3 (0.51) NTRK1NTRK3NTRK2KITCSF1R
SCHEMBL395533 0.86 FLT3 (0.48) NTRK1KITFLT3PDGFRBFLT4
SCHEMBL396893 0.85 FLT3 (0.47) NTRK1KITFLT3PDGFRBFLT4
SCHEMBL398246 0.84 NTRK1 (0.53) NTRK1NTRK3NTRK2KITFLT3
SCHEMBL396192 0.83 NTRK1 (0.61) NTRK1NTRK3NTRK2CSF1RSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 — — US claimed
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 — — US disclosed
Send feedback